Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($40.21); post-transaction worth based connected April 16, 2026 marketplace adjacent ($41.40).

• How does the standard of this merchantability comparison to Roger Jeffs' humanities disposition pattern?
  This transaction, astatine 53,300 shares, exceeds the mean size of anterior sell-only events (mean: 20,782 shares), reflecting some a larger azygous disposition and a simplification successful disposable stock capacity, arsenic holdings person declined by implicit 60% successful the past year.

• What does the exclusive usage of indirect holdings (Serendipity BioPharma LLC) successful this merchantability indicate?
  All shares sold successful this filing were attributed to Serendipity BioPharma LLC, suggesting a continued penchant for managing liquidity done indirect vehicles portion maintaining important nonstop ownership.

• How worldly is the simplification comparative to his full and indirect holdings?
  The 53,300 shares sold correspond 2.02% of full holdings and 3.56% of the indirect position, indicating a measured simplification alternatively than a large-scale withdrawal, with meaningful ownership remaining successful some buckets.

• Was this merchantability opportunistic oregon pre-scheduled?
  The filing confirms the commercialized was executed nether a Rule 10b5-1 plan, classifying it arsenic a routine, pre-scheduled liquidity lawsuit alternatively than a discretionary market-timed action.

* 1-year terms alteration calculated arsenic of marketplace adjacent April 17, 2026.

• Key products see YUTREPIA, an inhaled adust pulverization formulation of treprostinil for pulmonary arterial hypertension, and the organisation of generic treprostinil injection successful the United States.

• Revenue is chiefly generated done the development, manufacturing, and commercialization of proprietary and generic therapies targeting unmet aesculapian needs successful the pulmonary vascular illness market.

• The company's main customers are healthcare providers and institutions treating patients with pulmonary arterial hypertension successful the United States.